Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

October 6, 2014

Study Completion Date

October 16, 2014

Conditions

Renal ImpairmentType 2 Diabetes Mellitus

Interventions

DRUG

Ertugliflozin

Single oral administration of 3 X 5 mg tablets.